180 Therapeutics is a clinical stage biopharmaceutical company focused on the discovery and development of novel biologic therapies for the treatment of fibrosis, a process of excessive undesirable scarring which is a major unmet medical need in many different human diseases.


Our unique approach of evaluating human disease tissue has enabled the discovery of new novel therapeutic approaches through the understanding of how scarring and fibrosis causes disease.

Our Science

Our pipeline of novel TNF-based therapeutics for the treatment of fibrosis includes a treatment of Dupuytren’s disease, a disease which affects up to 4% of the population, which is in Phase 2b clinical development with support from the Wellcome Trust, UK.